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A B S T R A C T
Background
Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease. Adding a second antiplatelet drug to
aspirin may produce additional benefit for those at high risk and those with established cardiovascular disease.
Objectives
To quantify the benefit and harm of adding clopidogrel to standard long-term aspirin therapy for preventing cardiovascular events in
people at high risk of cardiovascular disease and those with established cardiovascular disease.
Search methods
The searches have been updated: CENTRAL (Issue 3 2009), MEDLINE (2002 to September 2009) and EMBASE (2002 to September
2009).
Selection criteria
All randomized controlled trials comparing long term use of aspirin plus clopidogrel with aspirin plus placebo or aspirin alone in
patients with coronary disease, ischemic cerebrovascular disease, peripheral arterial disease, or at high risk of atherothrombotic disease
were included.
Data collection and analysis
Data on mortality, non-fatal myocardial infarction, non-fatal stroke, unstable angina, heart failure, revascularizations, major and minor
bleeding, and all adverse events were collected. The overall treatment effect was estimated by the pooled odds ratio (OR) with 95%
confidence interval (CI) using a fixed-effect model (Mantel-Haenszel).
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Main results
No new studies were identified from the updated searches. A total of two RCTs were found: the CHARISMA and the CURE study.
The CURE study enrolled only patients with a recent non-ST segment elevation acute coronary syndrome. The use of clopidogrel plus
aspirin, compared with placebo plus aspirin, was associated with a lower risk of cardiovascular events (OR: 0.87, 95% CI 0.81 to 0.94;
P<0.01) and a higher risk of major bleeding (OR 1.34, 95% CI 1.14 to 1.57; P<0.01). Overall, we would expect 13 cardiovascular
events to be prevented for every 1000 patients treated with the combination, but 6 major bleeds would be caused. In the CURE trial,
for every 1000 people treated, 23 events would be avoided and 10 major bleeds would be caused. In the CHARISMA trial, for every
1000 people treated, 5 cardiovascular events would be avoided and 3 major bleeds would be caused.
Authors’ conclusions
The available evidence demonstrates that the use of clopidogrel plus aspirin is associated with a reduction in the risk of cardiovascular
events and an increased risk of bleeding compared with aspirin alone. Only in patients with acute non-ST coronary syndrome benefits
outweigh harms.
P L A I N L A N G U A G E S U M M A R Y
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease
Low-dose aspirin as antiplatelet therapy is still the drug of choice for preventing cardiovascular events, but the protection aspirin gives
to people at high risk of cardiovascular events is only relatively modest. This review of 28,165 people in two trials where clopidogrel
was given in addition to antiplatelet treatment found that in patients with acute coronary syndromes the benefit - a reduction in
cardiovascular events - outweighs the harm of major bleeding. However, clopidogrel plus aspirin has no clear positive risk-benefit profile
in people at high risk of cardiovascular events (multiple atherothrombotic risk factors) or in people with established cardiovascular
disease (known coronary disease, ischemic cerebrovascular disease or peripheral arterial disease) but not presenting with an acute
coronary syndrome, and the combination should not be prescribed routinely to prevent cardiovascular disease.
B A C K G R O U N D
Description of the condition
Cardiovascular disease is a leading cause of mortality and mor-
bidity worldwide. An estimated 17 million people die of cardio-
vascular disease each year (WHO 2003). Primary and secondary
prophylaxis aims to modify major risk factors. Antiplatelet ther-
apy improves the survival of patients with manifest cardiovascular
disease (Patrono 2001).
Aspirin (acetyl salicylic acid) as antiplatelet therapy is the drug of
choice, due to its good cost effectiveness profile (Gaspoz 2002).
Based on a recent meta-analysis, the Antithrombotic Trialists’ Col-
laboration (ATC) concluded that aspirin is protective in most pa-
tients at risk of cardiovascular events. In this analysis, patients
at risk were those with acute myocardial infarction or ischemic
stroke, unstable or stable angina, previous myocardial infarction,
stroke or cerebral ischemia, peripheral arterial disease or atrial
fibrillation (ATC 2002). Although the relative risk reduction of
death, myocardial infarction and stroke in these patients was ap-
proximately 20% (ATC 2002), the protection with antiplatelet
therapy in patients with a high risk of cardiovascular disease re-
mains unsatisfactory in absolute terms. Moreover, low compli-
ance and adverse effects limit the cost effectiveness of aspirin
alone (Morant 2003). Adding a second antiplatelet drug to as-
pirin may produce additional benefits in some clinical circum-
stances (ATC 2002). New antiplatelet drugs and preventive strate-
gies have been developed and studied. Previously published re-
views and protocols in The Cochrane Library discuss both the
importance of antiplatelet drugs and their limits in the preven-
tion of cardiovascular disease, mainly in peripheral artery dis-
ease (Cosmi 2004; Dorffler-Melly 2003a; Dorffler-Melly 2003b;
Dorffler-Melly 2005; Hankey 2004; Robless 2007; Robless 2004;
Van de Laar 2005).
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Description of the intervention
The combination treatment of clopidogrel plus aspirin could
be a potential strategy to reduce cardiovascular disease. The an-
tiplatelet drug clopidogrel, a thienopyridine derivative, has been
compared with aspirin (CAPRIE 1996) and combined with as-
pirin (CREDO 2002; CURE 2001) and demonstrated a good sa-
fety profile in these studies. In addition, as confirmed by a system-
atic review by the UK National Institute for Health and Clinical
Excellence (NICE), it was suggested that people with non-ST seg-
ment elevation acute coronary syndrome benefit from aspirin in
combination with clopidogrel compared to treatment with aspirin
alone (NICE 2004). A recent Health and Technology Assessment
(HTA) economic evaluation and systematic review of clopidogrel
in combination with aspirin for the treatment of non-ST segment
elevation acute coronary syndromes confirmed the clinical and
cost effectiveness of the combination therapy (HTA 2004). Given
that the antiplatelet effect is consistent in different populations,
any age, sex and risk subgroups could derive benefit from the com-
bination therapy.
Adverse effects
Besides bleeding associated with combined antiplatelet use,
thienopyridine-induced neutropenia is a major concern (Hankey
2004). Clopidogrel is the preferred thienopyridine, because it has a
good safety profile. However, although the risk is lower compared
to other thienopyridines, neutropenia has been described during
clopidogrel use (CAPRIE 1996). Indeed, the US Food and Drugs
Administration found 37 cases of clopidogrel-associated throm-
botic thrombocytopenic purpura (TTP) between 1998 and 2002.
TTP occurs usually within 2 weeks of drug initiation, and has a
high mortality if not treated promptly (Zakarija 2004).
The aim of this systematic review (an update of a Cochrane re-
view, Squizzato A, Keller T, Middeldorp S. Clopidogrel plus as-
pirin versus aspirin alone for preventing cardiovascular disease.
Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.:
CD005158) is to assess the effects of the combination of clopido-
grel and aspirin compared with aspirin alone in the primary and
secondary prevention of cardiovascular disease.
O B J E C T I V E S
1. To quantify the potential benefit of adding clopidogrel to long-
term aspirin therapy for preventing acute myocardial infarction,
ischemic stroke and vascular deaths in people at high risk of car-
diovascular disease (multiple atherothrombotic risk factors) and
in people with established cardiovascular disease (known coronary
disease, ischemic cerebrovascular disease and peripheral arterial
disease)
2. To quantify the potential harm of the combined therapy in
terms of bleeding (major and minor bleeding, blood transfusion,
hemorrhagic stroke or gastric bleeding) and adverse effects (i.e.
renal failure, TTP, neutropenia, low platelets, gastric complaints
and diarrhea)
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials comparing use of aspirin plus clopi-
dogrel with aspirin plus placebo or aspirin alone, with follow-up
> 30 days.
Types of participants
Studies were included if participants had known coronary dis-
ease, ischemic cerebrovascular disease, peripheral arterial disease,
or were at high risk of atherothrombotic disease.
Types of interventions
Aspirin plus clopidogrel versus aspirin plus placebo or aspirin
alone. No other platelet aggregation inhibitors as co-intervention
were accepted.
Types of outcome measures
Primary
All cardiovascular events.
Secondary
Mortality from myocardial infarction.
Non-fatal myocardial infarction.
Unstable angina.
Heart failure.
Mortality from ischemic stroke.
Non-fatal ischemic stroke.
Revascularization procedures.
Mortality from cardiovascular causes.
All-cause mortality.
Major bleeding (hemorrhagic stroke, gastric bleeding, any
bleeding requiring blood transfusion, any bleeding causing a
hemoglobin level drop of > 2 mg/dL, or hospitalization).
Minor bleeding.
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All adverse events (i.e. renal failure, thrombotic thrombocytopenic
purpura (TTP), neutropenia, low platelets, gastric complaints, di-
arrhea, skin rash)
Search methods for identification of studies
Electronic searches
The Cochrane Central Register of Controlled Trials (CENTRAL)
on The Cochrane Library (Issue 3 2009), MEDLINE (2002 to
September 2009) and EMBASE (2002 to September 2009) were
searched. MEDLINE and EMBASE have been systematically
searched centrally for RCTs, or possible RCTS, and these have
been added to CENTRAL. Because of this we searched MED-
LINE and EMBASE only from 2002. No language restrictions
were applied.
The search strategies used previously (Appendix 2) were updated
for the search in 2009 (Appendix 1).
A standard RCT filter (Dickersin 1994) was used in the MED-
LINE search.
Searching other resources
We performed an extensive manual search, checking of ref-
erences from original articles and pertinent reviews. In ad-
dition we searched websites for recent or ongoing trials (
www.epi.bris.ac.uk/cochrane/cardi.html, www.cardiosource.com,
www.clinicaltrial.gov, www.controlled-trials.com).
We searched (electronic) databases and aimed to identify as many
systematic reviews andmeta analysis as possible. Studies were iden-
tifiedusing theDatabase of Abstracts of Reviews of Effects (DARE)
on The Cochrane Library.
Data collection and analysis
Study selection
Two review authors (TK and AS in the first version and AS and ER
in this updated version) independently selected potentially eligible
references from the search. The references were rejected if it could
be determined from the title and/or abstract that the study was
not suitable for inclusion in this review. The full text of the study
was obtained when an article could not be excluded with certainty.
Excluded studies were compared and any disagreement was solved
through discussion between the reviewers.
Risk of bias assessment
We assessed the risk of bias in the included studies according to
the recommendations in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2008). We scored each of the
following points as ’yes’, ’no’, or ’unclear’ (where ’yes’ indicates
that the study is less open to bias) and report them in a ’Risk of
bias’ table.
(1) Method of randomisation (selection bias)
Methods of randomisation using date of birth, date of admission,
hospital numbers, or alternation are not appropriate because they
do not allow each study participant to have the same chance of
receiving each intervention.
(2) Concealment of allocation (indication bias)
Adequate measures to conceal allocations are central randomisa-
tion; serially numbered, opaque, sealed envelopes; or other de-
scriptions with convincing concealment.
(3) Blinding of investigators and patients (performance bias)
(4) Blinding of outcome assessment (detection bias)
(5) Adequate follow up (attrition bias)
Attrition bias refers to systematic differences between the com-
parison groups in the loss of participants from the study. We will
carefully check the reporting of withdrawals, dropouts, protocol
deviations, and losses to follow up. It is adequate when more than
90% of the patients have completed follow up and when reasons
for withdrawals, dropouts, protocol deviations, and losses to fol-
low up are clearly reported.
(6) Other possible bias
Based on these criteria, we divided studies into the following three
categories:
A - all quality criteria met: low risk of bias;
B - one or more of the quality criteria only partly met: moderate
risk of bias;
C - one or more criteria not met: high risk of bias.
To avoid selection bias, we did not reject any study because of
methodological characteristics or any subjective quality criteria,
except non-randomised studies. However, we planned to examine
differences in study methods in sensitivity analyses.
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Data extraction
Data were independently extracted using a predefined extraction
form. A consensus meeting was used to deal with differences in
the extracted data. No combined endpoints were extracted.
Authors were contacted for additional unpublished data. Data
were extracted for all groups and subgroups together: coronary
disease with and without drug-eluting stent (DES) or non-DES,
ischemic cerebrovascular disease, peripheral arterial disease, or pa-
tients at high risk of atherothrombotic disease.
The following data were extracted:
General information: published/unpublished, title, authors,
source, country, year of publication, duplicate publications.
Trial characteristics: design, duration, randomization (and
method), allocation concealment (and method), blinding (out-
come assessors), checking of blinding.
Intervention: loading dose, dosage, duration of treatment.
Participants: exclusion criteria, total number and number in com-
parison groups, gender/age, similarity of groups at baseline, with-
drawals/losses to follow-up.
Outcome: mortality from myocardial infarction, non-fatal my-
ocardial infarction, unstable angina, heart failure, mortality from
stroke, non fatal stroke, revascularizations, all-cause mortality, ma-
jor bleeding (hemorrhagic stroke, gastric bleeding, any bleeding
requiring blood transfusion, any bleeding causing haemoglobin
level drop of > 2 mg/dL), minor bleeding, all adverse events (i.e.
renal failure, TTP, neutropenia, low platelets, gastric complains,
diarrhea, skin rash).
’All cardiovascular events’ was calculated by summing available
secondary outcomes (fatal myocardial infarction, non-fatal my-
ocardial infarction, unstable angina, heart failure, fatal ischemic
stroke, non-fatal ischemic stroke, mortality from cardiovascular
causes other than myocardial infarction and ischemic stroke) for
each trial. Any trial definition of ’all cardiovascular events’ was not
taken in to account and no data were extracted. Revascularization
procedures were excluded from the primary outcome to reduce the
potential for bias. Many episodes of acute coronary events would
have been followed by revascularization, leading to double count-
ing of outcomes.
Data analysis
Datawere analysedwith RevMan version 4.2.2.Quantitative anal-
ysis of outcome was based on an intention-to-treat principle. The
measure of effect for each study was the odds ratio (OR) with
95% confidence interval (CI). The overall treatment effect was es-
timated by the pooledORwith 95%CI using a fixed-effect model
(Mantel-Haentzel). Each test for significance was two-tailed. Fun-
nel plots were used to assess for evidence of publication bias (Egger
1997). Sensitivity analysis was used to take into account the in-
fluence of study quality. The main value of this review is in ex-
amining whether long-term administration of clopidogrel has a
consistency of effect across all patients, but subgroup analyses
were performed to assess the benefit in particular predefined sub-
groups. People with peripheral arterial disease have already been
the subject of several Cochrane systematic reviews (Dorffler-Melly
2003a;Dorffler-Melly 2003b;Dorffler-Melly 2005;Robless 2007;
Robless 2004).
Heterogeneity
We assessed heterogeneity with the Mantel-Haentszel chi-square
test and I² test (Higgins 2003). For the first method trial data was
considered to be heterogeneous if P<0.10, for the second method
an I2 value < 30% indicates mild heterogeneity, 30% to 50%
moderate heterogeneity and >50% severe heterogeneity. In case
of significant heterogeneity, an attempt was made to explain the
differences based types of participants and study design difference.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Our updated search found 5047 references. We excluded 4798
references because they were not RCTs, were duplicates or inves-
tigated different topics. From abstracts, we excluded 55 references
because a non-eligible intervention was tested, 129 references be-
cause a non-eligible population was tested and 35 references be-
cause only data on acute administration was available (< 30 days).
Two references were for two ongoing studies. We retrieved the re-
maining 28 full text papers for inspection. Of these, 15 were ex-
cluded (three because no clinical endpoints were reported (two re-
ported data on the same population); three because only data in the
first 30 days were available; four because clopidogrel and placebo
were administered for less than 30 days; one because it was a com-
parison of 1 month and 6 months of clopidogrel; four (reporting
one trial) because clopidogrel was administered for 1month in the
aspirin-alone group). Further information of these excluded stud-
ies are given in the section Characteristics of excluded studies. Of
the remaining 13 publications, one was a reference for FASTER
2007 (previously an ongoing study) which has been excluded be-
cause data were not available in the manuscript and the authors
did not provide additional information. One was an additional
reference for the excluded study CARESS 2005. Therefore, a total
of 11 references reporting 2 studies was included (CHARISMA
2006; CURE 2001; Characteristics of included studies. Addition-
ally, three ongoing trials, which were potentially eligible, were also
identified from a search of online trial registers, giving a total of
five ongoing studies (Characteristics of ongoing studies).
In the Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance (CHARISMA) study
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a total of 15,603 people at high risk for a cardiovascular event were
randomized either to clopidogrel (75 mg per daily) plus low-dose
aspirin (75 to 162 mg per day) or to placebo plus low-dose aspirin
(CHARISMA 2006). In the clopidogrel plus aspirin and in the
placebo plus aspirin group, these are the baseline characteristics,
respectively: median age and range, 64.0 (39.0-95-0) and 64.0
(45.0-93.0); gender, 29.7% and 29.8% female; ethnicity, 80.4%
and 79.9% White, 9.9% and 10.7% Hispanic, 5.0% and 5.0%
Asian, 3.2% and 3.0% Black, 1.5% and 1.4% other. The trial
was multicenter, including th following countries: Argentina, Aus-
tralia, Austria, Belgium, Brazil, Canada, Czech Republic, Den-
mark, Finland, France, Germany, Greece, Hungary, Italy, Mexico,
The Netherlands, Norway, Poland, Portugal, Russia, Spain, South
Africa, Sweden, Switzerland, Turkey, United Kingdom, United
States. People were eligible for the trial if they were 45 years of
age or older and had one of the following conditions: multiple
atherothrombotic risk factors, documented coronary disease, doc-
umented cerebrovascular disease, or documented symptomatic pe-
ripheral arterial disease. After a median of 28months of follow-up,
a predefined primary efficacy endpoint was composed including:
the first occurrence of myocardial infarction, stroke (of any cause),
or death from cardiovascular causes (including hemorrhage). The
principal secondary efficacy endpoint was a composite of first oc-
currence of the primary endpoint, or hospitalization for unstable
angina, a transient ischemic attack, or a revascularization proce-
dure (coronary, cerebral, peripheral). The primary safety endpoint
was severe bleeding, according to the Global Utilization of Strep-
tokinase and Tissue Plasminogen Activator for Occluded Coro-
nary Arteries (GUSTO) definition, which includes fatal bleed-
ing and intracranial hemorrhage, or bleeding that caused hemo-
dynamic compromise requiring blood or fluid replacement, in-
otropic support, or surgical intervention (GUSTO 1993). Both
primary efficacy and primary safety endpoints were not signifi-
cantly in favour of any treatment.
In theClopidogrel inUnstable Angina toPreventRecurrent Events
(CURE) study a total of 12,562 people with a non-ST-segment-
elevation acute coronary syndrome were randomized to receive
either clopidogrel (a loading dose, 300 mg orally, followed by 75
mg daily) or placebo plus aspirin (recommended dose 75-325 mg)
(CURE 2001). In the clopidogrel plus aspirin and in the placebo
plus aspirin group, these are the baseline characteristics, respec-
tively: mean age, 64.2 ± 11.3 and 64.2 ± 11.3; gender, 38.7%
and 38.3% female; no data are available for ethnicity. The trial
was multicenter, including th following countries: Argentina, Aus-
tralia, Austria, Belgium, Brazil, Canada, Czech Republic, Den-
mark, Finland, France, Germany,Greece,Hungary, Ireland, Israel,
Italy, Mexico, The Netherlands, New Zealand, Norway, Poland,
Portugal, South Africa, Spain, Sweden, Switzerland, United King-
dom, United States. After a mean follow-up of 9 months, a prede-
fined primary endpoint was composed including: death from car-
diovascular causes, non-fatal acute myocardial infarction, or stroke
(ischemic and hemorrhagic). A secondary combined endpoint was
a composite of the primary endpoint and refractory ischemia. The
safety endpoint of bleeding was defined as life threatening, se-
vere (requiring two or more units of blood transfusions), or mi-
nor. Eight additional reports of the original CURE study were re-
trieved by the search. A specific benefit was found for clopidogrel,
mainly due to a decreased risk of non-fatal myocardial infarction.
However, no beneficial effect of clopidogrel was seen on several
other outcomes, including fatal myocardial infarction and cardio-
vascular death. Minor, major and specific bleedings such as gastric
bleeding or bleeding requiring transfusion of more than two units
of blood, occurred more often in the clopidogrel group compared
to placebo (a statistically significant difference).
All authors were contacted, but none provided additional data.
Only theCHARISMA study randomized people without evidence
of cardiovascular disease, but separate findings for these primary
patients were not presented and could not be obtained from the
trialists; consequently a comparison between efficacy of treatment
in primary versus secondary prevention cannot be made.
Risk of bias in included studies
The CHARISMA and the CURE studies were both double blind,
placebo controlled, randomized controlled trials. The study proto-
col was published in advance, before the end of the study. Based on
the previously described criteria of quality assessment, we marked
these studies as A, indicating that all quality criteria were met and
that the data extracted from these studies have a low risk of bias.
Both studies were funded by the pharmaceutical companies who
developed and sell clopidogrel.
Effects of interventions
Data from two trials with a total of 28,165 people were available.
The primary outcome in the CURE study was the sum of the fol-
lowing outcomes: fatal myocardial infarction, non-fatal myocar-
dial infarction, unstable angina, fatal ischemic stroke and non-
fatal ischemic stroke. The primary outcome in the CHARISMA
study was the sum of the following outcomes: non-fatal myocar-
dial infarction, non-fatal ischemic stroke and mortality from all
cardiovascular causes.
The CURE trial, confined to people with acute non-ST segment
coronary syndromes, showed definite evidence of benefit from
treatment (all cardiovascular events: OR 0.84, 95% CI 0.77 to
0.93) (Analysis 1.1) and an increase in major bleeding (OR 1.39,
95% CI 1.14 to 1.70) (Analysis 2.1). The number needed to treat
to avoid one cardiovascular event was 43, and the number needed
to treat to cause one major bleed was 99. For every 1000 people
treated for an average of 9 months, 23 events would be avoided
and 10 major bleeds would be caused.
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In theCHARISMA trial, which randomized people at high cardio-
vascular risk defined either in terms of pre-existing cardiovascular
diseases or risk factors, the effects of treatment were less marked
and were consistent with the play of chance (OR 0.92, 95% CI
0.81 to 1.04) (Analysis 1.1). There was only weak evidence of an
increase inmajor bleeding (OR1.25 (0.97 to 1.63)) (Analysis 2.1).
The number needed to treat to avoid 1 cardiovascular event was
194, and the number needed to treat to cause 1 major bleed was
300. For every 1000 people treated for an average of 28 months, 5
cardiovascular events would be avoided and 3 major bleeds would
be caused.
The pooled findings showed that, compared with aspirin alone,
clopidogrel plus aspirinwas associatedwith a small reduction in the
risk of having a cardiovascular event during long-term follow-up
(more than 30 days; minimum 6 months, maximum 28 months)
(OR: 0.87, 95% CI 0.81 to 0.94; P < 0.01) (Analysis 1.1). In
absolute terms, out of 1000 people treated with clopidogrel plus
aspirin, 101 people had a cardiovascular event, compared with 114
people treated with aspirin alone (risk difference: 1.3%, 95% CI
1% to 2%).
A significant increase in bleeding was seen in people treated with
clopidogrel plus aspirin. Compared with aspirin alone, the risk
of having a major bleeding during 1 year of treatment was 34%
higher in the clopidogrel plus aspirin group (OR 1.34, 95% CI
1.14 to 1.57; P < 0.01) (Analysis 2.1) with an absolute excess of
6 per 1000 patients treated with the combination for 1 year (25
versus 19, risk difference 0.6%, 95% CI 0% to 1%).
Overall, we would expect 13 cardiovascular events to be prevented
for every 1000 people treated with clopidogrel plus aspirin but 6
major bleeds would be caused.
D I S C U S S I O N
This systematic review of RCTs on the effect of long-term (>30
days) administration of clopidogrel plus lowdose aspirin compared
with long-term low dose aspirin alone for preventing cardiovascu-
lar disease in patients at high risk revealed 10 publications of two
original RCTs. In these trials a benefit of clopidogrel was reported
based on composite predefined endpoints only in theCURE study,
but with an increased risk of major and minor bleedings. After
extracting relevant clinical outcomes we combined these compo-
nents in an overall endpoint of all cardiovascular events (as defined
previously). We showed that the findings were consistent between
the two trials conducted on different clinical groupswith an overall
beneficial effect of long-term clopidogrel plus aspirin but this was
also associated with a significant increased risk of major bleeding.
For a correct interpretation of these data, some comments are nec-
essary. Several single secondary outcomes were not available in the
published papers, and could not be obtained from the trial in-
vestigators. This means that the overall treatment effect may be
estimated with bias as published results from particular outcomes
may be correlated with the size of the effect. For this reason we
decided to report only the primary outcome (all cardiovascular
events) and themain safety outcome (major bleeding). For the pri-
mary outcome, as reported above, available outcomes combined
are similar but not identical: for CHARISMA, unstable angina
data were not available, and fatal events were reported differently.
Combined endpoints should always be interpreted with caution.
For example, in the CURE study the potential beneficial effect of
clopidogrel plus aspirin on non-fatal myocardial infarction is not
extended to fatal myocardial infarction, unstable angina or cardio-
vascular death, although the risk for heart failure was somewhat
diminished.
Offsetting the beneficial antithrombotic effect of clopidogrel is
the clear increased risk of major and minor bleeding that has
been demonstrated during long-term use of clopidogrel plus as-
pirin compared with aspirin alone in both clinical groups. The
CHARISMA study investigated a population of high risk people
for atherothrombotic disease with or without evidence of cardio-
vascular disease, which is exactly the overall and subgroup types
of patients we planned to analyse. Unfortunately, only a few sec-
ondary outcomes were reported and available data on subgroup
populations (i.e. people with coronary disease with and without
DES or non-DES, ischemic cerebrovascular disease, peripheral ar-
terial disease, or with established cardiovascular disease, multiple
atherothrombotic risk factors, or those at high risk) were insuffi-
cient to derive secondary outcomes in this review or to conduct
meaningful subgroup analyses. The authors told us that they are
not allowed to provide CHARISMA data without Sanofi-Aventis
permission.
The CURE study enrolled patients with a recent non-ST segment
elevation acute coronary syndrome, and showed strong evidence
of benefit for the primary combined outcome of cardiovascular
events. By contrast, the CHARISMA study showed a non-signifi-
cant reduction of the combination therapy compared with aspirin
alone (OR 0.92, 95% CI 0.81 to 1.04), suggesting insufficient
evidence to support the use of treatment with clopidogrel plus
aspirin in non-acute patients at high risk of cardiovascular dis-
ease. Indeed, when the absolute treatment effects are examined in
the CHARISMA trial, the events avoided and the major bleeding
caused are quite similar.
Data from the CURE study suggest that the main benefit of com-
bination therapy is in the initial period. Therefore, it is probable
that clopidogrel in combination with ASA was associated with a
even smaller reduction in the risk of having a cardiovascular event
during long term follow-up to an average of 9 months. Given that
we excluded trials with less than 30 days of treatment, a definitive
7Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
conclusion on the early effects of treatment and the optimal dura-
tion of treatment are not possible. In an update to our review we
will include such trials in order to compare short term and long
term treatment effects as an explicit objective in acute coronary
syndromes.
In a CURE sub-group analysis (CURE 2001), the author reported
data between 30 days and 1 year after randomization. The exclu-
sion of patients who had an event in the first 30 days may have
undermined the balance achieved by randomization in the groups.
For this reason, these data are potentially biased and any inter-
pretation is difficult. However, the National Institute of Health
and Clinical Excellence (NICE 2004), has issued guidance based
on the CURE trial findings for health professionals in England
stating that 12 months treatment with clopidogrel plus aspirin
is cost-effective in patients with non-ST segment acute coronary
syndromes despite the increased risk of bleeding.
We identified five ongoing RCTs that potentially fit with our in-
clusion/exclusion criteria. Both included studies were funded by
the pharmaceutical companies who developed and sell clopido-
grel. This is a potential limitation and, therefore, data should be
interpreted with caution. Both Sanofi-Aventis and Bristol-Myers
Squibb did not provide us with additional information. Ongoing
studies will increase the available evidence, but mainly for spe-
cific subgroups of people at high risk of cardiovascular disease be-
cause of clear evidence of pre-existing atherothrombotic disease
(ischemic cerebrovascular disease, peripheral artery disease, coro-
nary disease).
Based on the available evidence, we can demonstrate a small, sta-
tistically non-significant beneficial effect of adding clopidogrel to
long-term administration of aspirin, but a significantly increased
risk of bleeding, in people at high risk of atherothrombotic dis-
ease without evidence of cardiovascular disease, and in people with
evidence of cardiovascular disease. In acute coronary syndrome
the picture is clearer, with evidence of benefits outweighing major
bleeding events.However, it is unclear whether the beneficial effect
is largely due to early post-acute event combination therapy and
is smaller in the long term. Future studies will provide additional
data to assess whether specific subgroups (most notably patients
with coronary disease who have undergone percutaneous coronary
intervention) may benefit from long-term combined antiplatelet
therapy with clopidogrel and aspirin.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Given the available evidence and until new data are published,
clinicians should not add clopidogrel to standard long-term aspirin
therapy for preventing cardiovascular disease in people at high risk
of cardiovascular disease and in those with established cardiovas-
cular disease. In patients with acute non-ST coronary syndromes,
there is evidence of benefit outweighing harms caused by major
bleeding and combination treatment should be considered.
Implications for research
From a public health perspective, given the high prevalence of
atherothrombosis, even a small benefit may be desirable. The re-
sults from ongoing trials will clarify the real risk-benefit of long-
term clopidogrel and aspirin combination therapy versus aspirin
alone in specific subgroup populations (ischemic cerebrovascular
disease, peripheral arterial disease and coronary surgery). If a real
benefit exists in any subgroup, data fromongoing trials will suggest
the optimal duration of combination therapy, and which throm-
botic and hemorrhagic variables can modify the risk-benefit pro-
file. Moreover, as other CHARISMA data are available, the pub-
lication of all thrombotic and bleeding outcomes and subgroup
analyses are advisable to better understand on which type of peo-
ple the research should be focused. At this time, it is not advis-
able to start new RCTs until new data from the ongoing studies
are available. Finally, forthcoming trials should uniformly present
outcomes, in order to avoid many of the problems we have experi-
enced in being unable to get the relevant data and to permit easier
systematic reviewing of the RCTs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CHARISMA 2006
Methods Randomized controlled trial.
Participants 15,603 people at high risk of a cardiovascular event (both primary and secondary pre-
vention)
Interventions Clopidogrel plus aspirin (n = 7802) versus placebo plus aspirin (n = 7801)
Outcomes Primary efficacy endpoint: composite of the first occurrence of myocardial infarction,
stroke (of any cause), or death from cardiovascular causes (including hemorrhage).
Principal secondary efficacy endpoint: composite of first occurrence of the primary end-
point, or hospitalization for unstable angina, a transient ischemic attack, or a revascu-
larization procedure (coronary, cerebral, peripheral).
Primary safety endpoint: severe bleeding, which includes fatal bleeding and intracranial
hemorrhage, or bleeding that caused hemodynamic compromise requiring blood or fluid
replacement, inotropic support, or surgical intervention
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes
Allocation concealment? Yes
Blinding?
All outcomes
Yes
Incomplete outcome data addressed?
All outcomes
Yes
Free of selective reporting? Yes
Free of other bias? No Pharmaceutical industry funded
CURE 2001
Methods Randomized controlled trial.
Participants 12,562 people with acute non-ST elevation coronary syndrome.
Interventions Clopidogrel plus aspirin (n = 6259) versus placebo plus aspirin (n = 6303)
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CURE 2001 (Continued)
Outcomes First primary outcome: composite of death from cardiovascular causes, non-fatal my-
ocardial infarction, or stroke.
Second primary outcome: composite of the first primary outcome or refractory ischemia.
Secondary outcomes: severe ischemia, heart failure and the need for revascularization.
Safety-related outcomes: bleeding complications, which were categorized as life-threat-
ening, major (two or more units of blood), or minor
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes
Allocation concealment? Yes
Blinding?
All outcomes
Yes
Incomplete outcome data addressed?
All outcomes
Yes
Free of selective reporting? Yes
Free of other bias? No Pharmaceutical industry funded
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akbulut 2004 No clinical end-points were reported.
Azar 2006 No clinical end-points were reported.
CARESS 2005 Clopidogrel and placebo was administered for only 7 days.
Cassar 2005 Only data for the first 30 days of therapy administration.
CLARITY-TIMI 28 2005 Only data for the first 30 days of combined clopidogrel-aspirin administration
COMMIT 2005 Clopidogrel and placebo was administered only until discharge or for up to 4 weeks in hospital
CREDO 2002 The placebo-allocated group received clopidogrel for 1 month after PCI
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(Continued)
FASTER 2007 No single clinical endpoints were reported in the published manuscript. Investigators did not provide
additional data
Jagroop 2004 No clinical endpoints were reported.
Pekdemir 2003 Comparison of 1 month versus 6 months of clopidogrel after PCI
Steinhubl 2006 Only data for the first 28 days of therapy administration and on different clopidogrel loading doses
Xydakis 2004 Clopidogrel and placebo were administered for only 5 days.
Zhao 2003 Clopidogrel and placebo were administered for only 2 weeks.
Characteristics of ongoing studies [ordered by study ID]
ASAP-CABG
Trial name or title ASpirin And Plavix following Coronary Artery Bypass Grafting
Methods Randomised controlled trial
Participants Patients undergoing coronary artery bypass graft with or without the use of cardiopulmonary bypass
Interventions Clopidogrel 75 mg daily plus aspirin 81 mg compared with aspirin 81 mg alone
Outcomes Graft stenosis, TIMI major and minor bleeding. 52 days follow-up
Starting date July 2010
Contact information http://www.clinicaltrial.gov
Notes Estimated study completion date: July 2012
CASCADE
Trial name or title Clopidogrel After Surgery for Coronary Artery Disease (CASCADE trial)
Methods Randomised controlled trial
Participants Patients undergoing primary multi-vessel coronary artery bypass graft with at least two saphenous vein grafts,
with or without the use of cardiopulmonary bypass
Interventions Clopidogrel 75 mg daily plus aspirin compared with aspirin alone
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CASCADE (Continued)
Outcomes Vein graft intimal area, vein graft angiographic patency, incidence of major adverse coronary events, major
bleeding events. One year follow-up
Starting date 2005
Contact information http://www.clinicaltrial.gov
Notes According tohttp://www.clinicaltrial.gov, the trial was completed on June 25th, 2010.Wewillmake reasonable
attempts to obtain information from published data and include them in the next update
CASPAR
Trial name or title Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease (CASPAR trial)
Methods Randomised controlled trial
Participants Patients receiving a below knee bypass graft for the treatment of peripheral arterial disease
Interventions Clopidogrel 75 mg daily versus placebo (on a background of aspirin 75-100 mg daily)
Outcomes Primary patency, limb salvage and survival, cardiovascular death,myocardial infarction, stroke, any amputation
above the ankle, ankle brachial pressure index (ABPI) changes from baseline
Starting date September 2004
Contact information http://www.controlled-trials.com
Notes According to http://www.clinicaltrial.gov, the trial was completed on September 17th, 2009. We will make
reasonable attempts to obtain information from published data and include them in the next update
MIRROR Trial
Trial name or title MIRROR trial: Follow-up Management of Peripheral Arterial Intervention With Clopidogrel
Methods Randomised controlled trial
Participants Peripheral arterial disease which requires intervention.
Interventions Clopidogrel or placebo.
Outcomes Platelet activation, the effect on macro- and microcirculation will be assessed as well as clinical endpoints
Starting date 2005
Contact information http://www.clinicaltrial.gov
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MIRROR Trial (Continued)
Notes Estimated study completion date: October 2008 (last update in http://www.clinicaltrial.gov was in 2007)
SPS3
Trial name or title Secondary Prevention of Small Subcortical Strokes (SPS3 trial)
Methods Randomised controlled trial
Participants One of the lacunar stroke clinical syndromes lasting > 24 hours within the past 6 months
Interventions Clopidogrel plus aspirin versus aspirin alone.
Outcomes Recurrent strokes and reduction in cognition (no other endpoints reported)
Starting date 2003
Contact information http://www.clinicaltrial.gov
Notes Estimated study completion date: June 2011
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D A T A A N D A N A L Y S E S
Comparison 1. PRIMARY OUTCOME
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All cardiovascular events 2 28165 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.81, 0.94]
Comparison 2. MAIN SAFETY OUTCOME
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major bleeding 2 28165 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [1.14, 1.57]
WH A T ’ S N E W
Last assessed as up-to-date: 27 February 2010.
Date Event Description
9 August 2010 New citation required but conclusions have not changed New author added.
9 August 2010 New search has been performed Searches have been re-run to September 2009. No new
studies were included in this update
H I S T O R Y
Protocol first published: Issue 1, 2005
Review first published: Issue 3, 2007
Date Event Description
8 September 2008 Amended Converted to new review format.
9 March 2007 New citation required and conclusions have changed Substantive amendment
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